It has been postulated that hepcidin may provide a better marker of iron deficiency than the routine biochemical tests in current use, thereby allowing more precise identification of patients with anaemia who likely to respond to iron therapy, whether intravenous or oral. The gene discussed is HAMP; the disease is nutritional disorder.